An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer-Reference-Cited by-同舟云学术

An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer

Published:2011-07 Issue:10 Volume:47 Page:1511-1520
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Moehler M.,Mueller A.,Hartmann J.T.,Ebert M.P.,Al-Batran S.E.,Reimer P.,Weihrauch M.,Lordick F.,Trarbach T.,Biesterfeld S.,Kabisch M.,Wachtlin D.,Galle P.R.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference52 articles.

1. Estimates of cancer incidence and mortality in Europe in 2008;Ferlay;Eur J Cancer,2010

2. Global cancer statistics, 2002;Parkin;CA Cancer J Clin,2005

3. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data;Wagner;J Clin Oncol,2006

4. Capecitabine and oxaliplatin for advanced esophagogastric cancer;Cunningham;N Engl J Med,2008

5. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction;Dank;Ann Oncol,2008

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pembrolizumab in combination with trastuzumab for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer;Annals of Medicine & Surgery;2024-06-21

2. KIRREL promotes the proliferation of gastric cancer cells and angiogenesis through the PI3K/AKT/mTOR pathway;Journal of Cellular and Molecular Medicine;2023-11

3. Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer;Frontiers in Oncology;2023-06-12

4. Recent Trends and Advancements in the Diagnosis and Management of Gastric Cancer;Cancers;2022-11-15

5. Successes and failures of angiogenesis blockade in gastric and gastro-esophageal junction adenocarcinoma;Frontiers in Oncology;2022-09-23